文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

镰状细胞病造血干细胞移植后供者细胞植入评估:当前与未来方法综述

Assessment of donor cell engraftment after hematopoietic stem cell transplantation for sickle cell disease: A review of current and future methods.
PubMed 文献 · Am J Hematol · 2022-06-02

本综述批判性审视镰状细胞病(SCD)造血干细胞移植(HSCT)后供者植入的现有评估方法,指出全血嵌合率主要反映白细胞嵌合而红细胞植入与白细胞呈非线性关系,存在局限;并介绍红细胞特异性流式细胞术、红细胞特异性RNA分析及源自有核红细胞的血浆游离DNA定量等新兴技术。

要点

  • 全血嵌合率主要反映白细胞嵌合,因红细胞与白细胞植入呈非线性关系,评估SCD患者植入状态存在局限。
  • 直接检测红细胞嵌合的方法虽存在但未常规使用。
  • 红细胞特异性流式细胞术、红细胞特异性RNA分析及有核红细胞来源血浆游离DNA定量是具前景的替代方法。

核心结论

  • 全血嵌合率主要反映白细胞嵌合,在评估SCD患者HSCT后植入状态方面存在局限,因红细胞与白细胞呈非线性植入。

研究设计与样本

  • 综述,检索范围未报告。

主要发现

  • 目前嵌合率检测在全血样本上进行,主要反映白细胞嵌合。
  • 直接检测红细胞嵌合的方法存在但未常规使用。
  • 具前景的替代方法包括红细胞特异性流式细胞术、红细胞特异性RNA分析及源自有核红细胞的血浆游离DNA定量。

临床怎么用

  • 作者认为,准确评估HSCT后红细胞植入对评价移植物状态及早期干预治疗或预防移植物排斥至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hematopoietic stem cell transplantation (HSCT) is the only established curative treatment for sickle cell disease (SCD), a debilitating red blood cell (RBC) disorder with significant prevalence worldwide. Accurate assessment of RBC engraftment following HSCT is essential to evaluate the status of the graft and can enable early intervention to treat or prevent graft rejection. Currently, chimerism measurement is performed on whole blood samples, which mainly reflect white blood cell (WBC) chimerism. This approach has limitations in assessing engraftment in patients with SCD because RBCs engraft non-linearly with WBCs. Direct measures of RBC chimerism exist but are not routinely used. In this review, we critically examine the current methodologies for assessing donor engraftment; highlight the limitations of these different methods, and present emerging and novel technologies with the potential to improve clinical monitoring of RBC engraftment post-HSCT for SCD. Promising alternative methodologies include RBC-specific flow cytometry, RBC-specific RNA analysis, and quantification of plasma cell-free DNA derived specifically from nucleated RBCs.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Lewis J, Greenway SC, Khan F, et al. Assessment of donor cell engraftment after hematopoietic stem cell transplantation for sickle cell disease: A review of current and future methods. Am J Hematol. 2022. PMID: 35583381. doi:10.1002/ajh.26599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。